DR. KEVIN MARK SLAWIN, M.D.
Urology at Fannin St, Houston, TX

License number

Texas J3225

Personal information

See more information about KEVIN MARK SLAWIN at radaris.com

Name

Address

Phone

Kevin Slawin, age 63

2336 Underwood St, Houston, TX 77030

Kevin M Slawin, age 63

2336 Underwood St, Houston, TX 77030

Kevin M Slawin

6560 Fannin St, Houston, TX 77030

(713) 798-4001

Kevin Slawin

6400 Fannin St, Houston, TX 77030

(713) 366-7800

Kevin M Slawin, age 63

3000 Bissonnet St, Houston, TX 77005

Professional information

See more information about KEVIN MARK SLAWIN at trustoria.com

Physician, Inventor, Entrepreneur, Pioneer Robotic Surgeon, Biotech Executive, Prostate Cancer Expert

Position:

Founder at Vanguard Urologic Institute, Founder, Executive Chairman, and Chief Medical Officer at Bellicum Pharmaceuticals, Inc., Director of Urology - MMH TMC at Memorial Hermann Healthcare System

Location:

Houston, Texas

Industry:

Biotechnology

Work:

Vanguard Urologic Institute - Memorial Hermann - Texas Medical Center since 2007 - Founder Bellicum Pharmaceuticals, Inc. - Texas Medical Center, Houston, TX since 2003 - Founder, Executive Chairman, and Chief Medical Officer Memorial Hermann Healthcare System - Houston, TX since Jul 2007 - Director of Urology - MMH TMC Baylor College of Medicine 1994 - 2007 - Director, The Baylor Prostate Center

Education:

Columbia University College of Physicians and Surgeons 1982 - 1986
M.D. Columbia University in the City of New York 1978 - 1982
B.A., Biochemistry

Skills:

Lifesciences, Urology, Surgery, Cancer, Treatment, Cancer Immunotherapy, Robotic Surgery, Prostate Cancer, Biotechnology Industry, Pharmacueticals, Clinical Strategy, Clinical Trials, Medical Diagnostics

Interests:

urologic surgical oncologist, prostate cancer specialist, robotic surgeon

Honor & Awards:

Best Doctors 2001 to present America's Top Doctors 2006 to present

Novel Forms Of Prostate Specific Antigen (Psa) Specific For Benign Prostatic Hyperplasia (Bph) And Methods Of Using Such

US Patent:

2003011, Jun 26, 2003

Filed:

Sep 24, 2002

Appl. No.:

10/252862

Inventors:

Stephen Mikolajczyk - San Diego CA, US
Tang Wang - Poway CA, US
Harry Rittenhouse - Del Mar CA, US
Robert Wolfert - San Diego CA, US
Kevin Slawin - Houston TX, US

Assignee:

Hybritech Incorporated and Baylor College of Medicine

International Classification:

C12Q001/68, G01N033/574, C07H021/04, C12N009/00, C12P021/02, C12N005/06, C07K016/30

US Classification:

435/006000, 435/007230, 435/069300, 435/183000, 435/320100, 435/325000, 536/023200, 530/388260

Abstract:

A substantially pure and isolated novel form of prostate specific antigen (PSA) is provided. The novel form of PSA of the present invention comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA. Preferably, the novel form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146. More preferably, the form of PSA contains at least two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA. The novel forms of PSA exist at an elevated level in patients suspected of having benign prostatic hyperplasia (BPH) and therefore may be used as a serum mark or an immunohistological marker to help distinguish BPH from prostate cancer. Antibodies recognizing the novel forms of PSA and immunoassays that detect and determine the novel forms of PSA of the present invention in a sample are also provided. Further provided are a kit and a method for detecting the novel forms of PSA for aiding in the differentiation of prostate cancer from BPH.

Inhibition Of The Sh2-Domain Containing Protein Tyr-Phosphatase, Shp-1, To Enhance Vaccines

US Patent:

2009012, May 14, 2009

Filed:

May 16, 2008

Appl. No.:

12/122146

Inventors:

Jonathan Levitt - Houston TX, US
Indu R. Ramachandran - Houston TX, US
Kevin M. Slawin - Houston TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 39/00, A61K 35/12, A61K 31/7088

US Classification:

4242771, 424 937, 514 44, 4241841

Abstract:

The invention describes the use of dendritic cell vaccines, wherein SHP-1 expression or activity is modulated in the dendritic cell. In particular, the invention provides dendritic cells (DC) transduced with an SHP1-shRNA adenovirus, or dominant negative (dn-SHP-1) or constitutively active (ca-SHP-1), and pulsed with an antigen. The methods and compositions of the invention are used for the prevention and/or treatment of cancers, other cell proliferation diseases and conditions, diseases caused by a pathogen, or autoimmune disorders.

Genetic Markers Associated With Benign Prostatic Hyperplasia

US Patent:

2006019, Aug 31, 2006

Filed:

Jan 25, 2006

Appl. No.:

11/339733

Inventors:

Jonathan Levitt - Houston TX, US
Kevin Slawin - Houston TX, US
Eduardo Canto - Houston TX, US
David Spencer - Houston TX, US
Michael Ittmann - Houston TX, US

Assignee:

BAYLOR COLLEGE OF MEDICINE - Houston TX

International Classification:

C12Q 1/68, G01N 33/574

US Classification:

435006000, 435007230

Abstract:

The present invention regards expression profiles of one or more nucleic acids indicative of the presence of, susceptibility to, and/or predicting response to therapy of benign prostatic hyperplasia (BPH) in an individual. The present invention identifies pathways not previously associated with BPH, therefore presenting novel diagnostic and therapeutic targets for the condition.

Method To Determine Outcome For Patients With Prostatic Disease

US Patent:

2003023, Dec 25, 2003

Filed:

Mar 14, 2003

Appl. No.:

10/389245

Inventors:

Kevin Slawin - Houston TX, US
Shahrokh Shariat - Dallas TX, US
Michael Kattan - New York NY, US
Peter Scardino - Manhattan NY, US

Assignee:

Baylor College of Medicine (by Slawin and Shariat)

International Classification:

C12Q001/70

US Classification:

435/005000

Abstract:

A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.

Method To Determine Prognosis After Therapy For Prostate Cancer

US Patent:

2003005, Mar 20, 2003

Filed:

Feb 7, 2002

Appl. No.:

10/071861

Inventors:

Kevin Slawin - Houston TX, US
Shahrokh Shariat - Houston TX, US

International Classification:

G01N033/574

US Classification:

435/007230

Abstract:

A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.

Induced Activation In Dendritic Cells

US Patent:

2008026, Oct 30, 2008

Filed:

Jun 30, 2008

Appl. No.:

12/165360

Inventors:

David Spencer - Houston TX, US
Brent Hanks - Houston TX, US
Kevin Slawin - Houston TX, US

International Classification:

A61K 31/7088, A61P 37/04

US Classification:

514 44

Abstract:

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

Method For Detection Of Micrometastatic Prostate Cancer

US Patent:

2003011, Jun 19, 2003

Filed:

Apr 22, 2002

Appl. No.:

10/128966

Inventors:

Kevin Slawin - Houston TX, US
Donald Tindall - Rochester MN, US
Charles Young - Rochester MN, US

Assignee:

Baylor College of Medicine, Hybritech Incorporated

International Classification:

C12Q001/68, C12P019/34

US Classification:

435/006000, 435/091200

Abstract:

Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.

Method To Predict Risk Of Bph Progression

US Patent:

2007013, Jun 14, 2007

Filed:

Sep 11, 2006

Appl. No.:

11/530763

Inventors:

Kevin Slawin - Houston TX, US
Michael Kattan - Cleveland Heights OH, US

International Classification:

G01N 33/53, G06F 19/00

US Classification:

435007100, 702019000

Abstract:

A method to predict benign prostatic hyperplasia symptom progression, acute urinary retention, need for surgical intervention and/or prostate cancer development in patients is provided.